Purchasing agent of Tarceva in India, purchasing Tarceva in India 18801374745 Tarceva

H', , H >Common name: Erlotinib Hydrochloride Tablets. [Ingredients] Each tablet contains m erlotinib (in the form of erlotinib hydrochloride). [Indications] It is used for the third-line treatment of locally advanced or metastatic non-small cell lung cancer that has failed two or more chemotherapy regimens. [Contraindications] It is prohibited for those who are allergic to this product and its ingredients. [Adverse Reactions] The most common adverse reactions are rash and diarrhea. The incidence rates of rash and diarrhea are % and % respectively. The median occurrence time of rash is days and the median occurrence time of diarrhea is days. Adverse reactions with an incidence rate greater than % include: rash, diarrhea, decreased appetite, fatigue, dyspnea, cough, nausea, infection, vomiting, stomatitis, itching, dry skin, conjunctivitis, keratoconjunctivitis, and abdominal pain. [Precautions] This product must be used under the guidance of doctors with experience in the use of such drugs, and can only be used in the national oncology drug clinical trial base or tertiary A hospitals. [Usage and Dosage] This product must be used under the guidance of doctors with experience in the use of such drugs, and can only be used in the national tumor drug clinical trial base or tertiary A hospitals. The recommended dose of erlotinib monotherapy for non-small cell lung cancer is m/day, taken at least one hour before or one hour after eating. Continue treatment until disease progression or intolerable toxicity occurs. There is no evidence that patients benefit from continuing treatment after progression.